Experimental protocol to investigate the efficacy of pralnacasan in DSS-induced colitis
Group | Solvent | Number | Administration Route | Pralnacasan | Mortality |
|---|---|---|---|---|---|
| mg/kg | |||||
| DSS + HEC | 0.5% HEC | 8 | p.o. | 0 | 1/8 |
| DSS + pralnacasan | 25% cremophor EL | 8 | i.p. | 50 b.i.d. | 0/8 |
| DSS + pralnacasan | 0.5% HEC | 8 | p.o. | 12.5 b.i.d. | 3/8 |
| DSS + pralnacasan | 0.5% HEC | 8 | p.o. | 50 b.i.d. | 0/8 |
| Control + pralnacasan | 25% cremophor EL | 2 | i.p. | 50 b.i.d. | 0/2 |
| Control + pralnacasan | 0.5% HEC | 2 | p.o. | 50 b.i.d. | 0/2 |